The company provides a direct‑to‑consumer saliva kit that generates FDA‑cleared genotyping reports on ancestry, health risks, carrier status and pharmacogenetics, delivered through a secure online portal. Customers can subscribe for continuous report updates and access optional exome sequencing or clinical blood tests via a telehealth workflow, with data stored using end‑to‑end encryption.

4D Molecular Therapeutics develops customized gene therapies using a proprietary vector platform optimized through directed evolution, targeting diseases in ophthalmology, pulmonology, and cardiology. Their products aim to provide curative treatments for conditions with significant unmet medical needs, such as reducing the treatment burden for wet age-related macular degeneration.

908 Devices provides handheld chemical analysis instruments that deliver laboratory‑grade detection of drugs, explosives, hazardous chemicals and gases at the point of need. Their portfolio—including the MX908 mass spectrometer, VipIR FTIR/Raman analyzer, XplorIR gas/vapor sensor, ProtectIR and ThreatID FTIR devices—offers rapid, trace‑level identification with cloud‑connected AI libraries and remote expert support for first responders, law‑enforcement, customs and hazmat teams.

A2 Biotherapeutics develops Tmod™, a precision-targeting T cell therapy platform that distinguishes solid tumors from normal cells by exploiting specific gene losses unique to cancer cells. This approach addresses the challenge of effective treatment for solid tumors while minimizing damage to healthy tissue.

Absci utilizes a generative AI-driven Integrated Drug Creation platform that combines AI modeling with scalable wet lab validation to design and optimize biologics for therapeutic applications. This approach significantly reduces the time from drug conception to clinical candidates, enabling the screening of billions of cells weekly and accelerating the development of effective treatments for patients.

Adaptive Biotechnologies provides a CLIA‑certified, NGS‑based minimal residual disease assay (clonoSEQ) with sensitivity to 10⁻⁶ and high‑coverage T‑cell and B‑cell receptor immunosequencing that generates >10⁶ clonotypes per sample. The resulting repertoire data are processed through proprietary bioinformatics pipelines and delivered via secure cloud dashboards and API endpoints for clinical laboratories, trial sponsors, and biopharma drug‑discovery programs.

Affina offers white-labeled, managed loyalty platforms that enhance customer engagement and drive repeat transactions through gamification and interactive marketplaces. Their solutions provide businesses with real-time data and insights to optimize loyalty strategies and increase customer lifetime value.

Alecto builds advanced digital platforms to strengthen organizational cybersecurity and privacy. Their solutions address complex threat landscapes for government and enterprise clients, enhancing digital defenses and resilience.

Aledade operates the largest network of independent primary care through its Accountable Care Organizations (ACOs), utilizing data analytics and guided workflows to enhance patient outcomes and financial sustainability for practices. By facilitating value-based care, Aledade enables over 1,900 practices to improve care coordination and achieve shared savings, impacting more than 2.5 million patients across the U.S.

AmplifyBio is a preclinical contract research organization (CRO) that provides drug discovery, characterization, and manufacturing services for small molecules, cell and gene therapies, and mRNA. The company addresses the need for efficient and scalable R&D solutions by offering end-to-end support from in vitro and in vivo safety studies to GMP manufacturing.

Amplo Biotechnology develops AAV-based gene therapies targeting the neuromuscular junction to treat genetic disorders such as Congenital Myasthenic Syndromes. Their lead candidates, AMP-101 and AMP-201, deliver the Dok-7 and Collagen Q proteins, respectively, to restore critical muscle function and address the underlying causes of these debilitating conditions.

Apella Technology offers an AI-powered surgical operations platform that enhances real-time decision-making and operational efficiency in the operating room. By providing predictive insights on case durations and staffing needs, the platform reduces administrative complexity and improves surgical workflow, leading to a 24% increase in surgery duration predictions compared to traditional electronic health records.

Exai Bio has developed a liquid biopsy platform that utilizes cell-free RNA profiling and artificial intelligence to detect cancer early through a simple blood draw. By analyzing orphan non-coding RNA sequences abundant in tumors, the platform provides actionable insights that enhance personalized treatment strategies for patients.

Imagen provides on-site diagnostic imaging services powered by proprietary AI software that enhances detection and documentation of medical conditions. This technology enables primary care practices to deliver immediate test results, improving early disease intervention and increasing patient satisfaction while enhancing financial performance.

Lunit develops AI-powered medical imaging solutions that enhance early-stage cancer detection and predict treatment responses for immunotherapy. By leveraging advanced algorithms, Lunit's technology increases the accuracy of cancer screenings and improves patient outcomes across over 3,800 healthcare sites in more than 50 countries.

Mnemo Therapeutics utilizes a novel approach to identify and target tumor-specific antigens that are shared across patients, enabling the development of personalized cancer therapies. This method addresses the challenge of limited druggable targets in oncology, enhancing treatment options for diverse patient populations.

Nomic develops the nELISA platform, a high-throughput proteomics technology that utilizes DNA nanotechnology to enable flexible multiplexing of protein profiling. This platform addresses the limitations of traditional immunoassays by providing rapid, precise quantification of over 200 cytokines, facilitating comprehensive analysis of the immune secretome.

ONI develops super-resolution microscopy tools, including the Nanoimager and Aplo Flow, to facilitate single-molecule imaging for researchers in various fields. Their technology simplifies sample preparation and data analysis, enabling more accurate and reproducible results in studies involving lipid nanoparticles and other biological samples.

Vector Biomed specializes in the design and GMP manufacturing of optimized Lentiviral vectors for clinical development, enabling rapid translation from therapeutic concepts to pre-clinical and clinical applications. The company addresses the need for high-quality, scalable vector production that meets specific requirements for gene expression and transduction efficiency.